Omeros (OMER) Total Current Liabilities (2010 - 2026)
Omeros (OMER) reported Total Current Liabilities of $59.4 million for Q1 2026, down 28.57% on a YoY basis from $83.2 million in Q1 2025, and down 23.85% sequentially from $78.1 million in Q4 2025.
Omeros (OMER) Total Current Liabilities (2010 - 2026) Analysis & Trends
Omeros (OMER) has 17 years of Total Current Liabilities data on file, last reported at $59.4 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities fell 28.57% year-over-year to $59.4 million; the trailing twelve-month figure through Mar 2026 stood at $59.4 million (down 28.57% YoY), and the FY2025 full-year result was $78.1 million, down 1.84% from the prior year.
- Total Current Liabilities slipped to $59.4 million in Q1 2026, from $78.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $147.2 million in Q3 2023 to a low of $35.1 million in Q1 2022.
- A 5-year average of $80.8 million and a median of $78.1 million in 2025 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities jumped 296.94% in 2023 and plunged 62.21% in 2024, its largest moves.
- Tracing OMER's Total Current Liabilities over 5 years: stood at $136.4 million in 2022, then plunged by 60.91% to $53.3 million in 2023, then surged by 49.16% to $79.5 million in 2024, then fell by 1.84% to $78.1 million in 2025, then dropped by 23.85% to $59.4 million in 2026.
- Business Quant data shows OMER's Total Current Liabilities at $59.4 million in Q1 2026, $78.1 million in Q4 2025, and $80.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Omeros | 739.31 Mn | 739.31 Mn | 9.31 Mn | 59.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.44 Mn |
| Dec 31, 2025 | 78.06 Mn |
| Sep 30, 2025 | 80.76 Mn |
| Jun 30, 2025 | 85.50 Mn |
| Mar 31, 2025 | 83.22 Mn |
| Dec 31, 2024 | 79.53 Mn |
| Sep 30, 2024 | 55.62 Mn |
| Jun 30, 2024 | 59.48 Mn |
| Mar 31, 2024 | 59.06 Mn |
| Dec 31, 2023 | 53.32 Mn |
| Sep 30, 2023 | 147.18 Mn |
| Jun 30, 2023 | 143.54 Mn |
| Mar 31, 2023 | 139.19 Mn |
| Dec 31, 2022 | 136.38 Mn |
| Sep 30, 2022 | 39.51 Mn |
| Jun 30, 2022 | 38.50 Mn |
| Mar 31, 2022 | 35.07 Mn |
| Dec 31, 2021 | 51.79 Mn |
| Sep 30, 2021 | 42.82 Mn |
| Jun 30, 2021 | 47.70 Mn |